未登录

S

Stefan Franzén

Institute of Medicine

H指数:37

被引数:7,389

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Excess risk of cardiovascular disease and mortality after amputation in type 2 diabetes: a nationwide population study from the Swedish National Diabetes Register

2型糖尿病截肢后心血管疾病和死亡风险的增加：一项来自瑞典国家糖尿病登记册的全国性人群研究

Cardiovascular Diabetology

IF10.6

2026-08-240

OA

Dimensionality Reduction Techniques for Improving Propensity Score Specification: An Application to a Cohort Study Using Claims Data

降维技术以改进倾向得分设定：一项关于使用理赔数据的队列研究应用

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

IF2.4

2025-11-240

PRE

Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-01-170

OAAI

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

ESC HEART FAILURE

IF3.7

2024-12-100

OAAI

Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia

高钾血症后通过维持而不是减少肾素-血管紧张素-醛固酮系统抑制剂 (RAASi) 治疗来避免首次住院所需的估计数量

IF3

2024-08-210

OAAI

Do beta-blockers reduce negative intrusive thoughts and anxiety in cancer survivors? - An emulated trial

IF3.4

2024-04-110

OAAI

Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

ADVANCES IN THERAPY

IF4

2024-01-198

OAAI

Implantable cardioverter defibrillator and cardiac resynchronization treatment in people with type 2 diabetes: a comparison with age- and sex matched controls from the general population

CARDIOVASCULAR DIABETOLOGY

IF10.6

2024-01-061

OAAI

Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

NATURE METABOLISM

IF20.8

2024-01-049

OAAI

Risk Factors for and Risk of Peripheral Artery Disease in Swedish Individuals With Type 2 Diabetes: A Nationwide Register-Based Study

IF16.6

2023-11-022

OA

The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes

他汀类药物对无其他心血管疾病或糖尿病的初级保健高血压患者死亡率和心血管疾病的影响

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY

IF7.5

2023-06-279

OA

Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study

ADVANCES IN THERAPY

IF4

2023-05-0319

OAAI

The introduction of a weighted blanket was not associated with a reduced collection of pharmaceuticals prescribed for sleep disturbances in children: A register-based study

IF3.4

2023-05-014

PRE

Associations between new-onset postoperative atrial fibrillation and long-term outcome in patients undergoing surgical aortic valve replacement

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

IF3

2023-03-247

OA

Risk factor variability and cardiovascular risk among patients with diabetes: a nationwide observational study

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY

IF7.5

2023-03-1012

OA

Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study

IF16.6

2022-12-018

OAAI

Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes 10-Year and Lifetime Risk Prediction Models

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2022-12-015

OA

The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study

SCIENTIFIC REPORTS

IF3.9

2022-10-268

OAAI

Erratum. Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care (vol 44 pg2853-2858, 2022)

IF16.6

2022-08-100

OA

Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes

SCIENTIFIC REPORTS

IF3.9

2022-07-115

OAAI